A man walks into a recovery program after a fourth relapse. He has been drinking heavily for twelve years. In that time he has tried three different antidepressants, none of which meaningfully lifted his mood. His addiction counselor sends him to a psychiatrist. The psychiatrist tells him the depression cannot be treated until the drinking stops. The cycle resumes.
This patient is not unusual. He is the rule.
Roughly thirty to forty percent of adults with alcohol use disorder also meet criteria for major depressive disorder, depending on the population studied. American addiction medicine has spent decades treating these as separate problems handled by separate clinicians. The standard playbook is to sober the patient up first, then attempt to treat the depression with a selective serotonin reuptake inhibitor. The trouble is that SSRIs perform poorly in actively drinking patients, and not much better in the early months of recovery, when relapse risk runs highest.
A systematic review presented at the American Society of Addiction Medicine annual meeting in San Diego in April 2026 suggested a different approach. The reviewers pooled data from PubMed and the Cochrane Library on ketamine trials in patients carrying both major depression and alcohol use disorder. Across the studies they assessed, ketamine produced two effects at once. Depressive symptoms dropped quickly, often within hours rather than weeks. Alcohol-related measures, including craving, consumption, and time to relapse, also improved.
What the data showed was one drug producing two clinical effects in the same patient, in the same infusion.
The Hidden Half of Alcohol Use Disorder
Comorbid depression in heavy drinkers is the rule, not an exception, and it shapes every clinical decision that follows. People who drink to manage depression are doing something neurochemically coherent. Alcohol acutely raises GABA, dampens glutamate, and provides a brief lift in dopamine. The depression often gets blamed on the drinking, but the temporal pattern usually runs the other way around. By the time these patients reach a treatment program, they have been self-medicating an untreated mood disorder for years.
Conventional rehab tends to miss this. Programs that treat addiction in isolation send patients home with abstinence skills but no relief from the underlying depression that drove the drinking in the first place. Relapse rates in this population sit between sixty and eighty percent in the first year. This is exactly the gap a dual-target medication can address. It is one of the reasons our Rescue From Rehab approach refuses to split mood and substance use into separate workups.
Why SSRIs Often Disappoint
Patients with comorbid depression and alcohol use disorder are typically left on antidepressants that were never studied in this population. The largest meta-analyses of SSRIs in alcohol-dependent patients with depression show small or absent benefits on mood and inconsistent effects on drinking. SSRIs take four to six weeks to reach a meaningful effect, which is precisely the window in which untreated depression drives early relapse. By the time the medication might have helped, the patient is back in a bar.
Some clinicians escalate to tricyclics or MAO inhibitors. These have a worse safety profile in a patient who might still be drinking, and they have not produced the dual-target effects we need.
This is also one reason the recent Lancet trial on semaglutide drew so much attention. Both ketamine and semaglutide work outside the serotonin system the older addiction pharmacopeia has been stuck on. We are watching a shift from neurotransmitter monoculture to a more useful pluralism.
Glutamate, Not Serotonin
Ketamine works on a different system entirely. It is an NMDA receptor antagonist, which means it blocks one of the brain's primary excitatory glutamate channels. The downstream effect is a burst of synaptic plasticity. New connections form quickly in the prefrontal cortex, and the brain regions that have grown rigid around depression and reward begin to remodel.
The same glutamate signaling is heavily disrupted in chronic alcohol exposure. When someone drinks daily for years, the brain compensates by upregulating NMDA receptors. Sudden abstinence then produces an excitotoxic state that contributes to anxiety, craving, and depressive relapse. Ketamine appears to soften this transition in ways SSRIs cannot, because SSRIs do not touch the glutamate system at all.
Across the nine randomized controlled trials in substance use disorders the ASAM 2026 review drew from (three in alcohol, three in cocaine, two in opioid use disorder, and one in nicotine), ketamine reduced cravings and improved retention in treatment when paired with structured psychotherapy. That last detail matters. Ketamine without therapy is a drug. Ketamine with therapy is a treatment.
This pattern fits what we have been seeing in our Intensive Brain Health Program with patients who carry both diagnoses. The infusion is one element of the protocol, but the part that holds is the work that happens between sessions, often with a neurocoach. The molecule opens a window. The therapy decides what goes through it.
What This Means for the Patient
If you have been told that your depression must wait until you stop drinking, or that your drinking is only a symptom of your depression, you have been given a false binary. The two conditions feed each other, and a treatment plan that addresses only one will fail the other.
What to ask of your treatment team: whether they will treat both diagnoses concurrently, what their position on glutamate-targeted medications is, and whether there is a structured psychotherapy component to any infusion protocol they offer. Whether recovery sticks has less to do with willpower than with whether the medicine you are being given matches the biology of what is wrong.
For readers earlier in the process, the Action Potential Supplements brain-nutrition formulations are a low-friction first step. They will not replace clinical care, but they support the same neurotransmitter systems that ketamine and structured therapy address at a higher dose. The science of recovery has moved past the willpower era. The treatment options should follow.